Ameritas Investment Partners’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-10,547
| Closed | -$32.1K | – | 3172 |
|
|
2024
Q4 | $32.1K | Hold |
10,547
| – | – | ﹤0.01% | 2425 |
|
|
2024
Q3 | $54.7K | Buy |
10,547
+2,258
| +27% | +$11.2K | ﹤0.01% | 2140 |
|
|
2024
Q2 | $21.3K | Hold |
8,289
| – | – | ﹤0.01% | 2583 |
|
|
2024
Q1 | $40.8K | Hold |
8,289
| – | – | ﹤0.01% | 2262 |
|
|
2023
Q4 | $72.9K | Hold |
8,289
| – | – | ﹤0.01% | 1937 |
|
|
2023
Q3 | $95.1K | Buy |
8,289
+1,400
| +20% | +$26.9K | ﹤0.01% | 1690 |
|
|
2023
Q2 | $174K | Buy |
6,889
+428
| +7% | +$13.3K | 0.01% | 1227 |
|
|
2023
Q1 | $208K | Hold |
6,461
| – | – | 0.01% | 1073 |
|
|
2022
Q4 | $217K | Buy |
6,461
+1,099
| +20% | +$25.1K | 0.01% | 1091 |
|
|
2022
Q3 | $144K | Hold |
5,362
| – | – | 0.01% | 1253 |
|
|
2022
Q2 | $74K | Hold |
5,362
| – | – | ﹤0.01% | 1715 |
|
|
2022
Q1 | $105K | Hold |
5,362
| – | – | ﹤0.01% | 1625 |
|
|
2021
Q4 | $88K | Hold |
5,362
| – | – | ﹤0.01% | 1761 |
|
|
2021
Q3 | $149K | Hold |
5,362
| – | – | 0.01% | 1432 |
|
|
2021
Q2 | $159K | Hold |
5,362
| – | – | 0.01% | 1421 |
|
|
2021
Q1 | $150K | Hold |
5,362
| – | – | 0.01% | 1401 |
|
|
2020
Q4 | $152K | Hold |
5,362
| – | – | 0.01% | 1306 |
|
|
2020
Q3 | $135K | Buy |
5,362
+345
| +7% | +$9.05K | 0.01% | 1256 |
|
|
2020
Q2 | $123K | Buy |
5,017
+978
| +24% | +$19.3K | 0.01% | 1284 |
|
|
2020
Q1 | $60K | Buy |
4,039
+268
| +7% | +$5.54K | ﹤0.01% | 1564 |
|
|
2019
Q4 | $61K | Hold |
3,771
| – | – | ﹤0.01% | 1806 |
|
|
2019
Q3 | $49K | Hold |
3,771
| – | – | ﹤0.01% | 1889 |
|
|
2019
Q2 | $49K | Buy |
3,771
+939
| +33% | +$11.8K | ﹤0.01% | 1927 |
|
|
2019
Q1 | $45K | Hold |
2,832
| – | – | ﹤0.01% | 1948 |
|
|
2018
Q4 | $57K | Hold |
2,832
| – | – | ﹤0.01% | 1732 |
|
|
2018
Q3 | $70K | Hold |
2,832
| – | – | ﹤0.01% | 1786 |
|
|
2018
Q2 | $78K | Buy |
2,832
+560
| +25% | +$16.8K | ﹤0.01% | 1702 |
|
|
2018
Q1 | $70K | Buy |
2,272
+303
| +15% | +$9.75K | ﹤0.01% | 1723 |
|
|
2017
Q4 | $70K | Hold |
1,969
| – | – | ﹤0.01% | 1726 |
|
|
2017
Q3 | $48K | Hold |
1,969
| – | – | ﹤0.01% | 1924 |
|
|
2017
Q2 | $52K | Buy |
1,969
+542
| +38% | +$12.1K | ﹤0.01% | 1879 |
|
|
2017
Q1 | $30K | Buy |
+1,427
| New | +$29.3K | ﹤0.01% | 2169 |
|
Other funds holding RVNC
Ameritas Investment Partners's RVNC Position: Q1 2025 in Review
Ameritas Investment Partners sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 10,547 shares — an estimated $32.1K sold.
Ameritas Investment Partners first reported a position in RVNC in Q1 2017 and held it in 32 quarters. The position peaked at $217K in Q4 2022. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- Ameritas Investment Partners reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- Ameritas Investment Partners sold 10,547 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $32.1K.
- Ameritas Investment Partners first reported a position in Revance Therapeutics, Inc. in Q1 2017 and held it in 32 quarters.
- Ameritas Investment Partners's Revance Therapeutics, Inc. position peaked at $217K in Q4 2022.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on Ameritas Investment Partners's 13F filing for Q1 2025, filed 12 May 2025.